MEG
NVAX icon

Millstone Evans Group’s Novavax NVAX Stock Holding History

Millstone Evans Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-400
Closed -$3.47K – 868
2025
Q3 		$3.47K Hold
400
– – ﹤0.01% 678
2025
Q2 		$2.52K Hold
400
– – ﹤0.01% 657
2025
Q1 		$2.56K Hold
400
– – ﹤0.01% 676
2024
Q4 		$3.22K Buy
+400
New +$3.86K ﹤0.01% 613

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millstone Evans Group's NVAX Position: Q4 2025 in Review

Millstone Evans Group sold out of Novavax (NVAX) in Q4 2025, closing a stake of 400 shares — an estimated $3.47K sold.

Millstone Evans Group first reported a position in NVAX in Q4 2024 and held it in 4 quarters. The position peaked at $3.47K in Q3 2025. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

  • Millstone Evans Group reported no remaining Novavax position as of Q4 2025 after selling out during the quarter.
  • Millstone Evans Group sold 400 Novavax shares in Q4 2025, an estimated $3.47K.
  • Millstone Evans Group first reported a position in Novavax in Q4 2024 and held it in 4 quarters.
  • Millstone Evans Group's Novavax position peaked at $3.47K in Q3 2025.
  • 235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Millstone Evans Group's 13F filing for Q4 2025, filed 2 Feb 2026.